Introduction for Tofacent 5 mg (Tofacitinib five mg):

Tofacent 5 mg is a partial and reversible janus kinase (JAK) inhibitor that prevents the body’s response to cytokine signals. Tofacent is used to treat adult patients with moderately to severe rheumatoid arthritis. Tofacitinib 5 also reduces inflammation, which helps to relieve pain in the joints, soreness, and swelling. Tofacent 5 also slows the spread of bone and arthritis in joints. Tofacitinib 5 may be taken alone or in conjunction with other medications. The tablets can be taken with or without meals, and it is recommended that you take them at the same time every day. Your dosage will be determined by your medical condition and the medications you are already taking. You should use it exactly as prescribed by your doctor.

Indications:

Tofacent 5 mg or Tofacitinib is a Janus kinase (JAK) inhibitor.
It can be used for the treatment of:
1.Tofacent 5 mg (Tofacitinib/Tofacitinib XR) is recommended for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).
2.Tofacent 5 mg (Tofacitinib/Tofacitinib XR)  is recommended for the treatment of adult patients with active psoriatic arthritis who experienced a poor response or intolerance to methotrexate or other disease-modifying antirheumatic medications (DMARDs).
3. Tofacent 5 mg (Tofacitinib) is used to treat adults with moderately to severely active ulcerative colitis (UC).
Limitations of use: Tofacitinib 5 mg (Tofacitinib/Tofacitinib XR) in combination with biologic DMARDs or potent such as :Azathioprine and cyclosporine are not encouraged.

Therapeutic Class: Immunosuppressant.

Pharmacology:

Rheumatoid arthritis is an autoimmune illness characterized by abnormal regulation of pro-inflammatory cytokines such as IL7, IL15, IL21, IL6, IFN-alpha, and IFN-beta. (3) Cytokines cause tissue inflammation and joint injury by boosting immune cell recruitment and activation via the Janus kinase signalling pathway.
Tofacitinib 5 mg  is a partial and reversible janus kinase (JAK) inhibitor that prevents the body’s response to cytokine signals. Tofacent 5 mg  inhibits JAKs, preventing the phosphorylation and activation of STATs. The JAK-STAT signaling system regulates the transcription of cells involved in hematopoiesis and immune cell activity. Tofacitinib 5 mg (Tofacitinib)  works by blocking the JAK-STAT pathway, reducing the inflammatory response. However, data suggests that it may potentially acquire efficacy via other mechanisms as well.

Dosage and Administration of Tofacent 5 mg Tablet:

For Rheumatoid Arthritis, Tofacent 5 mg twice daily or 11 mg once daily. Tofacitinib 5 mg once daily is the recommended dosage for people with moderate to severe renal impairment or moderate hepatic impairment.
For Psoriatic Arthritis, Tofacitinib 5 mg twice daily or 11 mg once daily. Tofacent 5 mg once daily is the recommended dosage for people with moderate to severe renal impairment or moderate hepatic impairment.

Side Effects of Tofacent 5 mg Tablet:

The most common side effects of Tofacent 5 are upper respiratory tract infection, nasopharyngitis, diarrhea, and headache. Nasopharyngitis, higher cholesterol levels, headache, upper respiratory tract infection, increased blood creatine phosphokinase, rash, diarrhea, and herpes zoster were reported in ≥5% of  Tofacent 5 treated ulcerative colitis patients.

Drug Interaction:

Tofacitinib 5 mg dosage should be adjusted in the presence of strong CP3A4 inhibitors (for example, ketoconazole).For strong CYP3A4 inducers (e.g., rifampin) avoid co administration with Tofacitinib 5 mg. Tofacent 5 mg (Tofacitinib) should not be taken with immunosuppressive drugs such as azathioprine, tacrolimus, or cyclosporine.

Use in Pregnancy and Lactation:

There are no sufficient or well-controlled tests in pregnant women. Tofacent 5 mg (Tofacitinib) should be taken during pregnancy only if the possible benefits justify the potential risks to the fetus. It is unclear whether Tofacitinib 5 mg  is excreted in human milk. As many medications are excreted in human milk and Tofacent 5 mg (Tofacitinib)  has the potential for major adverse reactions in breastfeeding infants, a decision should be made whether to quit breastfeeding or discontinue the drug, taking into consideration the drug’s importance to the mother.

Storage Conditions:

Tofacent 5 mg should be kept between 25°C and 30°C at room temperature. When a medication is no longer needed or has expired, dispose of it safely. Protect from sunlight and humidity. Keep Tofacent 5 mg and all medicines out of the reach of children.

See more Oncology medicine visit our Shop